Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 14/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eliglustat SCHEMBL4057024 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL4067738 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL419334 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| Eliglustat SCHEMBL21648647 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| Eliglustat SCHEMBL21252721 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL1085008 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL12091633 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| Eliglustat SCHEMBL4058275 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| SCHEMBL761669 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 | |
| Eliglustat SCHEMBL17636050 | 1.00 | UGCG (1.00) | UGCGHTR1APTGS1OPRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062254-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | ICM INST DU CERVEAU ET DE LA MOELLE EPINIERE (FR) | 2022-03-03 | — | — | US | claimed |
| US-11065238-B2 | Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2021-07-20 | — | — | US | claimed |
| EP-3534958-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | ICM - Institut du Cerveau et da la Moelle Epinière (FR) | 2019-09-11 | — | — | EP | claimed |
| US-20220062254-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | ICM INST DU CERVEAU ET DE LA MOELLE EPINIERE (FR) | 2022-03-03 | — | — | US | disclosed |
| US-11065238-B2 | Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2021-07-20 | — | — | US | disclosed |
| US-20190350913-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2019-11-21 | — | — | US | disclosed |
| EP-3534958-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | ICM - Institut du Cerveau et da la Moelle Epinière (FR) | 2019-09-11 | — | — | EP | disclosed |
| EP-2550965-B1 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORP (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2923699-B1 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | GENZYME CORP (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3318277-A1 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE FOR THE TREATMENT OF MOTOR NEURON DISEASES | Institut du Cerveau et de la Moelle Epiniere-ICM (FR) | 2018-05-09 | — | — | EP | disclosed |
| EP-2209473-B1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-8912177-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2014-12-16 | — | — | US | disclosed |
| US-8716327-B2 | Methods of treating fatty liver disease | GENZYME CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2550965-A2 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORPORATION (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8309593-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20090105125-A1 | Methods of Treating Fatty Liver Disease | GENZYME CORPORATION | 2009-04-23 | — | — | US | disclosed |
| EP-2032134-A2 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | Genzyme Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007134086-A2 | METHODS OF TREATING FATTY LIVER DISEASE COMPRISING INHIBITING GLUCOSPHINGOLIPID SYNTHESIS | GENZYME CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184021-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | UGCG 14/4885HTR1A 4502/4885PTGS1 1177/4885 |
| US-11065238-B2 | Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases | GBA1, SMN1; SMN2, GAA | UGCG 13/4885HTR1A 3677/4885PTGS1 1570/4885 |
| US-20190350913-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | GBA1, SMN1; SMN2, GAA | UGCG 13/4885HTR1A 3677/4885PTGS1 1570/4885 |
| US-20090105125-A1 | Methods of Treating Fatty Liver Disease | LIPC, GYS2, PNLIP | UGCG 7/4885HTR1A 3913/4885PTGS1 1157/4885 |
| US-20220062254-A1 | INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES | GBA1, SMN1; SMN2, GAA | UGCG 13/4885HTR1A 3677/4885PTGS1 1570/4885 |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | UGCG 27/4885HTR1A 3534/4885PTGS1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.